0000914475-24-000121.txt : 20240516 0000914475-24-000121.hdr.sgml : 20240516 20240516164047 ACCESSION NUMBER: 0000914475-24-000121 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240514 FILED AS OF DATE: 20240516 DATE AS OF CHANGE: 20240516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ABERNETHY MATT CENTRAL INDEX KEY: 0001724097 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24956254 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1715892031.xml FORM 4 X0508 4 2024-05-14 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001724097 ABERNETHY MATT 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Financial Officer 1 Common Stock 2024-05-14 4 M 0 15000 73.60 A 46528 D Common Stock 2024-05-14 4 S 0 15000 135.6551 D 31528 D Common Stock 2024-05-15 4 M 0 15000 73.60 A 46528 D Common Stock 2024-05-15 4 S 0 15000 140.2406 D 31528 D Non-Qualified Stock Option 73.60 2024-05-14 4 M 0 15000 73.60 D 2027-12-01 Common Stock 15000 30000 D Non-Qualified Stock Option 73.60 2024-05-15 4 M 0 15000 73.60 D 2027-12-01 Common Stock 15000 15000 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $135.00 to $137.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.48. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and the remaining 75% vested in 36 equal monthly installments beginning November 1, 2018. /s/ Darin Lippoldt, Attorney-in-Fact 2024-05-16